<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260810070608N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-08-24</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of interventions on flatfoot</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Immediate Effects of Foot Insole and Kinesio Taping on Postural Stability Using the Double-Leg to Single-Leg Stance Transition Test in Adults with Flexible Flatfoot</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-09-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/92416</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: This study will employ a randomized, three-period, three-treatment crossover design. Eligible participants will be randomly assigned to one of six possible intervention sequences (IBT, ITB, BIT, BTI, TIB, TBI) in a 1:1:1:1:1:1 allocation ratio using a permuted block randomization method with a fixed block size of six. Each block will contain all six sequences exactly once in a randomly determined order. Five complete blocks will be generated to achieve the target sample size of 30 participants. To ensure allocation concealment, group assignments will be placed in sequentially numbered, opaque, sealed envelopes by an independent administrator. Envelopes will be opened sequentially only after participant enrollment and completion of all baseline procedures, immediately before the first intervention session.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Flexible flatfoot.</hc_freetext>
      <i_freetext>Intervention 1: Insole condition. Due to the crossover design of this study, this group represents one of the 3 conditions available. All 30 participants in the study receive this condition according to the sequence group to which they are assigned. This study has a total of 6 sequence groups, which determine the order in which the conditions (insole, Kinesio tape, no intervention) are received in each session.To evaluate the immediate effect of the condition, the participant performs the test 30 minutes after receiving the condition (familiarization period). Intervention 2: Kinesio tape condition. Due to the crossover design of this study, this group represents one of the 3 conditions available. All 30 participants in the study receive this condition according to the sequence group to which they are assigned. This study has a total of 6 sequence groups, which determine the order in which the conditions (insole, Kinesio tape, no intervention) are received in each session.To evaluate the immediate effect of the condition, the participant performs the test 30 minutes after receiving the condition (familiarization period). Intervention 3: No intervention condition. Due to the crossover design of this study, this group represents one of the 3 conditions available. All 30 participants in the study receive this condition according to the sequence group to which they are assigned. This study has a total of 6 sequence groups, which determine the order in which the conditions (insole, Kinesio tape, no intervention) are received in each session.To evaluate the immediate effect of the condition, the participant performs the test 30 minutes after receiving the condition (familiarization period).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Amir Mohammad Shooryabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Rehabilitation Sciences, Nezam Alley, Shahnazari St. Madar Sq. Mirdamad Blv.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1348715459</zip>
        <telephone>+98 21 2222 8051</telephone>
        <email>amirshooryabi5@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh Azadinia</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Rehabilitation Sciences, Nezam Alley, Shahnazari St. Madar Sq. Mirdamad Blv.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1348715459</zip>
        <telephone>+98 21 2222 7124</telephone>
        <email>azadinia.fatemeh@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 18–35 years
Ability to stand and walk
Bilateral flatfoot
BMI less than 30
Foot Posture Index (FPI-6) score ≥ +6
Navicular Drop Test ≥ 10 mm
Able to read and write in Persian
Moderate physical activity level (IPAQ questionnaire)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>35 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Foot deformities (hallux valgus, hammer toe, etc.) and vestibular disorders
Use of medications/substances affecting the central nervous system
History of musculoskeletal injury within the last 6 months
High-intensity physical activity within 12 hours before test</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M21.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Flat foot [pes planus] (acquired)</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Insole condition. Due to the crossover design of this study, this group represents one of the 3 conditions available. All 30 participants in the study receive this condition according to the sequence group to which they are assigned. This study has a total of 6 sequence groups, which determine the order in which the conditions (insole, Kinesio tape, no intervention) are received in each session.To evaluate the immediate effect of the condition, the participant performs the test 30 minutes after receiving the condition (familiarization period).</i_keyword>
      <i_keyword>Kinesio tape condition. Due to the crossover design of this study, this group represents one of the 3 conditions available. All 30 participants in the study receive this condition according to the sequence group to which they are assigned. This study has a total of 6 sequence groups, which determine the order in which the conditions (insole, Kinesio tape, no intervention) are received in each session.To evaluate the immediate effect of the condition, the participant performs the test 30 minutes after receiving the condition (familiarization period).</i_keyword>
      <i_keyword>No intervention condition. Due to the crossover design of this study, this group represents one of the 3 conditions available. All 30 participants in the study receive this condition according to the sequence group to which they are assigned. This study has a total of 6 sequence groups, which determine the order in which the conditions (insole, Kinesio tape, no intervention) are received in each session.To evaluate the immediate effect of the condition, the participant performs the test 30 minutes after receiving the condition (familiarization period).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The mean of COP displacement. Timepoint: Assessments will be performed immediately after a 30-minute period(familiarization) following the application of each intervention, across 3 sessions with different conditions, each separated by an interval of at least 24 hours from the previous session. Method of measurement: Force plate, model 9260AA6, manufactured by Kistler.</prim_outcome>
      <prim_outcome>Mean absolute COP velocity. Timepoint: Assessments will be performed immediately after a 30-minute period(familiarization) following the application of each intervention, across 3 sessions with different conditions, each separated by an interval of at least 24 hours from the previous session. Method of measurement: Force plate, model 9260AA6, manufactured by Kistler.</prim_outcome>
      <prim_outcome>Mean peak absolute COP velocity. Timepoint: Assessments will be performed immediately after a 30-minute period(familiarization) following the application of each intervention, across 3 sessions with different conditions, each separated by an interval of at least 24 hours from the previous session. Method of measurement: Force plate, model 9260AA6, manufactured by Kistler.</prim_outcome>
      <prim_outcome>Mean COP displacement during contralateral push-off phase. Timepoint: Assessments will be performed immediately after a 30-minute period(familiarization) following the application of each intervention, across 3 sessions with different conditions, each separated by an interval of at least 24 hours from the previous session. Method of measurement: Force plate, model 9260AA6, manufactured by Kistler.</prim_outcome>
      <prim_outcome>Mean COP excursion range during contralateral push-off phase. Timepoint: Assessments will be performed immediately after a 30-minute period(familiarization) following the application of each intervention, across 3 sessions with different conditions, each separated by an interval of at least 24 hours from the previous session. Method of measurement: Force plate, model 9260AA6, manufactured by Kistler.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Temporal parameters during transition task including mean time to new stability point, mean duration of contralateral limb push-off phase. Timepoint: Assessments will be performed in each session, under one of (control/no intervention; insole; kinesio tape) conditions, a 24-hours washout period will be considered between sessions. There will be a 30-minute familiarization time with interventions in each session. Method of measurement: force plate.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-07-22</approval_date>
        <contact_name>School of Rehabilitation Sciences, Iran University of Medical Sciences</contact_name>
        <contact_address>School of Rehabilitation Sciences, Nezam Alley, Shahnazari St. Madar Sq. Mirdamad Blv. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
